Read by QxMD icon Read


Marek Jutel, Michael Rudert, Fabian Kreimendahl, Piotr Kuna
AIM: This multicenter randomized placebo-controlled double-blind clinical trial investigated which maintenance dose shows the optimal benefit-risk ratio for subcutaneous immunotherapy with a Dermatophagoides pteronyssinus allergoid preparation. OBJECTIVE: To evaluate four maintenance doses of the allergoid preparation versus placebo. METHODS: The late-phase reaction of the intracutaneous test was chosen as efficacy parameter and minimal dose of fluticasone required for asthma control...
August 9, 2018: Immunotherapy
Hans D Ochs, Isaac Melamed, Michael Borte, James N Moy, Barbara Pyringer, Ai Lan D Kobayashi, Alan P Knutsen, William Smits, Anna Pituch-Noworolska, Roger H Kobayashi
AIM: To assess the safety and efficacy of an intravenous immunoglobulin (IVIG) 10% preparation (Panzyga® ; Octapharma AG, Lachen, Switzerland) in predominantly antibody-deficient children with primary immunodeficiency disease. METHODS: Data from two prospective, open-label and noncontrolled multicenter Phase III studies of IVIG 10% that included 25 patients <16 years of age were analyzed for efficacy, pharmacokinetics and safety. RESULTS: The rate of serious bacterial infections was 0...
August 8, 2018: Immunotherapy
Christine Bangert, Tamara Kopp
Psoriasis is a chronic skin disorder driven by IL-23 and the downstream T-helper cell 17 (Th17) pathway. Tildrakizumab is a humanized monoclonal antibody selectively targeting the p19 subunit of IL-23, a key cytokine for Th17 cells. Here, we provide an overview of IL-23 in the context of psoriasis pathogenesis and review the results of the Phase I, II and III clinical trials for tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis in order to assess its efficacy, safety and clinical usefulness...
August 7, 2018: Immunotherapy
Ernesto Enrique, Dolores Hernández-Fernandez de Rojas, Pilar Alba, Isabel Flores, Noelia Colomer, Carmen Andreu, María Cruz Gómez-Fernández, Araitz Landeta, Juan Antonio Asturias, Alberto Martínez, Begoña Madariaga-Goirigolzarri
AIM: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis. PATIENTS & METHODS: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. RESULTS: Out of 470 administered doses, only 3.8% elicited systemic reactions (1.5% nonspecific and 2.3% grade I). Concerning the exploratory efficacy parameters: cutaneous reactivity at the final visit versus baseline was significantly decreased; specific titers of IgG and IgG4 increased significantly and patients showed a significant decrease in the rhinitis symptoms score...
October 2018: Immunotherapy
Melissa Bersanelli, Diana Giannarelli, Paola Castrignanò, Giuseppe Fornarini, Stefano Panni, Francesca Mazzoni, Marcello Tiseo, Sabrina Rossetti, Elisabetta Gambale, Ernesto Rossi, Anselmo Papa, Alessio Cortellini, Cristian Lolli, Raffaele Ratta, Maria Michiara, Michele Milella, Emmanuele De Luca, Mariella Sorarù, Claudia Mucciarini, Francesco Atzori, Giuseppe L Banna, Leonardo La Torre, Maria G Vitale, Francesco Massari, Sara E Rebuzzi, Gaetano Facchini, Giovanni Schinzari, Silverio Tomao, Simona Bui, Vanja Vaccaro, Giuseppe Procopio, Ugo De Giorgi, Matteo Santoni, Corrado Ficorella, Roberto Sabbatini, Antonio Maestri, Clara Natoli, Michele De Tursi, Massimo Di Maio, Elena Rapacchi, Annagrazia Pireddu, Teodoro Sava, Helga Lipari, Francesca Comito, Elena Verzoni, Francesco Leonardi, Sebastiano Buti
AIM: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. METHODS: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017. RESULTS: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24...
October 2018: Immunotherapy
Dass S Vinay, Byoung S Kwon
Immunomodulatory antibodies that directly trigger and reawaken suppressed T-cell effector function are termed 'checkpoint inhibitors'. CTLA-4 and PD-1/PD-L1 molecules are the most studied inhibitory immune check points against cancer and because of this therapeutic property have entered the clinic for treating a variety of tumor types. The results so far demonstrate a positive impact on cancer remission. Preclinical studies have demonstrated that targeting a number of other T-cell surface molecules including both positive and negative immune regulators, also possesses strong antitumor activity...
October 2018: Immunotherapy
Michael A Mitchell, Kevin Hogan, Kayvan Amjadi
A 61-year-old woman with locally advanced, high-grade urothelial cell carcinoma was treated with the anti-programmed death-ligand 1 antibody atezolizumab. She initially received neoadjuvant chemotherapy and surgery that led to clinical and radiographic remission at the time of atezolizumab initiation. Within 3 months she developed new mediastinal and hilar lymphadenopathy as well as pulmonary nodules in a pattern characteristic of pulmonary sarcoidosis. Mediastinal lymph node biopsy by endobronchial ultrasound demonstrated noncaseating granulomas without evidence of malignancy or infection...
October 2018: Immunotherapy
Jesús Castro-Poceiro, Agnès Fernández-Clotet, Julián Panés
Significant unmet needs remain in patients with Crohn's disease and perianal fistulas. Mesenchymal stromal cells have potent immunomodulatory actions. The Phase II studies reported efficacy of local injection of mesenchymal stromal cells to achieve closure of fistulas. A Phase III trial demonstrated that in patients with Crohn's disease and refractory complex perianal fistulas, a single injection of 120 × 106 cells was superior to local injection of placebo associated with the same surgical procedure, in obtaining closure of the fistula tracts together with absence of abscesses >2 cm, 24 weeks after the injection, a stringent combined primary end point...
October 2018: Immunotherapy
María Vázquez de la Torre, Maria Luisa Baeza, Laura Nájera, José Manuel Zubeldia
AIM: To compare the immunological and clinical changes induced by allergen-specific immunotherapy (AIT) using different adjuvants. MATERIALS & METHODS: Olea europaea pollen-sensitized mice were treated with olea plus aluminum hydroxide, calcium phosphate, monophosphoryl lipid A (MPL) or immunostimulatory sequences (ISS). RESULTS: Aluminum hydroxide seems to drive initially to a Th2-type response. Bacteria-derived adjuvants (MPL and ISS) skew the immune response toward Th1 and Treg pathways...
October 2018: Immunotherapy
Ahmad Tarhini, Agnes Benedict, David McDermott, Sumati Rao, Apoorva Ambavane, Komal Gupte-Singh, Javier Sabater, Corey Ritchings, Valerie Aponte-Ribero, Meredith M Regan, Michael Atkins
AIM: To evaluate the cost-effectiveness of treatment sequences with checkpoint inhibitors in patients with BRAF wild-type melanoma. MATERIALS & METHODS: Using a discrete event simulation model, cost and health outcomes were estimated. Pooled data from CheckMate 067/069 trials were used to calculate survival outcomes including treatment-free interval extrapolated over a patient's lifetime. Costs accounted for treatment, administration, toxicity, and disease management...
October 2018: Immunotherapy
Sara Elena Rebuzzi, Giacomo Bregni, Massimiliano Grassi, Azzurra Damiani, Michele Buscaglia, Sebastiano Buti, Giuseppe Fornarini
Immunotherapy is associated with different response patterns compared with chemotherapy and targeted therapy, including delayed response and stabilization after progression (pseudoprogression). According to new immuno-based response criteria, immunotherapy can be continued after radiological progression when a clinical benefit is observed. We report a case of an advanced renal cell carcinoma patient treated with nivolumab, who developed clinical benefit and delayed radiological response after initial progression...
September 2018: Immunotherapy
Yang Liu, Bridget M Crawford, Tuan Vo-Dinh
Cancer has been a significant threat to human health with more than eight million deaths each year in the world. Therefore, there is a significant need for novel technologies to effectively treat cancer and ultimately reduce cancer recurrences, treatment costs, number of radical cystectomies and mortality. A promising therapeutic platform for cancer is offered by nanoparticle-mediated therapy. This review highlights the development and applications of various nanoparticle platforms for photo-induced hyperthermia and immunotherapy...
September 2018: Immunotherapy
Avivit Brener, Yael Lebenthal, Hagar Interator, Orit Horesh, Avital Leshem, Naomi Weintrob, Neta Loewenthal, Shlomit Shalitin, Marianna Rachmiel
Promising findings of α-1 antitrypsin (AAT) intervention in mice models of Type 1 diabetes (T1D) led researchers to investigate AAT as a therapeutic modality for β-cell preservation in recent-onset T1D patients. Our prospective, open-label Phase I/II extension study demonstrated that the administration of multiple repeated AAT infusions (up to 36) to AAT-sufficient pediatric T1D patients is safe and well-tolerated. Long-term surveillance of participants (up to 5 years) from diabetes onset revealed normal growth and pubertal progression through adolescence to attainment of full puberty and near adult height...
September 2018: Immunotherapy
Lingdi Zhao, Yonghao Yang, Wei Li, Lu Han, Hongwei Lin, Quanli Gao
Melanoma is the most common type of skin cancer in both men and women in the USA. The standard treatment modality for advanced melanoma is immunotherapy, either alone or in combination. As single-agent immunotherapy is usually inadequate, combined immunotherapy might be a good choice and combined treatment modalities appropriate for melanoma need to be explored. Herein, we report a case of metastatic melanoma successfully treated with combined therapy of tumor-infiltrating lymphocytes and nivolumab. Complete remission was achieved approximately 4 months after the initiation of treatment...
September 2018: Immunotherapy
Sarah B Goldberg, Abhijit A Patel
No abstract text is available yet for this article.
September 2018: Immunotherapy
Qianshuo Lu, Li Zuo, Bao Dong, Yu Yan, Bing Yang
Immune-complex-mediated membranoproliferative glomerulonephritis (MPGN) is a new concept that refers to MPGN with immunoglobulin and C3 deposition in the kidney based on immunofluorescence examination. It is associated with pathological autoantibodies production. Rituximab, as an immunosuppressive agent, can eliminate B cells selectively. We reported a case that a patient with immune-complex-mediated MPGN and HCV infection, but no cryoglobulinemia, responded well to the treatment of low-dosage of rituximab and steroids...
September 2018: Immunotherapy
Elie El Rassy, Rita Maria Khoury Abboud, Nathalie Ibrahim, Tarek Assi, Fouad Aoun, Joseph Kattan
Until recently, tyrosine kinase inhibitors (TKI) were the only approved drugs for the first-line treatment of metastatic renal cell carcinoma (mRCC). Emerging trials of immune checkpoint inhibitors (ICI)-based regimens have shown survival benefits over the standard TKI. These studies challenge a paradigm shift in the management of mRCC concerning the identification of the subgroup of patients that would benefit from ICI in treatment-naive mRCC, the possibility of treatment discontinuation between TKI and ICI, and the sequencing of surgery and systemic treatment...
September 2018: Immunotherapy
Caterina Fumagalli, Elena Guerini-Rocco, Davide Vacirca, Antonio Passaro, Filippo de Marinis, Massimo Barberis
No abstract text is available yet for this article.
September 2018: Immunotherapy
Joanne Ern Chi Soh, Nadiah Abu, Rahman Jamal
The identification of cancer testis antigens (CTAs) has been an important finding in the search of potential targets for cancer immunotherapy. CTA is one of the subfamilies of the large tumor-associated antigens groups. It is aberrantly expressed in various types of human tumors but is absent in normal tissues except for the testis and placenta. This CTAs-restricted pattern of expression in human malignancies together with its potential immunogenic properties, has stirred the interest of many researchers to use CTAs as one of the ideal targets in cancer immunotherapy...
September 2018: Immunotherapy
Huihui Chi, Jialin Teng, Chengde Yang, Yutong Su
Administration of anti-TNFα agents has become a mainstay in the treatment of chronic inflammatory arthritis such as rheumatoid arthritis (RA) and spondyloarthritis. Adverse events, including infections and allergic reactions, have been reported. Malignancies are rare but potentially life threatening. The existence of bone tumor in those patients is very rare, only five cases of bone tumors were mentioned in juvenile idiopathic arthritis (JIA) in the literature. We describe three patients in whom bone neoplasms developed after years of anti-TNFα therapy for JIA or juvenile ankylosing spondylitis (JAS)...
September 2018: Immunotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"